FASLODEX (Fulvestrant) 250 mg
Product Overview
| Generic Name | FASLODEX (Fulvestrant) 250 mg |
| Brand Name(s) | FASLODEX |
| Category | Antineoplastic / Cancer |
| Form | PFS, solution for intramuscular inj. 250 mg/5 mL |
| Strength | 250 mg/5 mL (50 mg/mL) |
| Therapeutic Class | Estrogen receptor antagonist |
| ATC Code | L02BA03 |
Manufacturing & Regulatory
| Manufacturer | AstraZeneca |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 197M2005 SSA / SSA IV / CLAVE: 010.000.5880.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Units |
| Shelf Life | 36 months |
| Storage | Store in cool, dry place (supplier); protect from light; refrigerate |
| Incoterms | EXW 30049049 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | CTD proprietary; available under commercial agreement/license |
Special Notes
FASLODEX (Fulvestrant) 250 mg/5 mL IM injection; indicated for estrogen receptor–positive, locally advanced or metastatic breast cancer in postmenopausal women; as monotherapy or combined with palbociclib.